3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Phase NA
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
27
Neoplasms
22
Breast Neoplasms
20
Neoplasm Metastasis
18
Colorectal Neoplasms
16
Stomach Neoplasms
15
Recurrence
15
Prostatic Neoplasms
15
Carcinoma, Hepatocellular
12
Pancreatic Neoplasms
11
Ovarian Neoplasms
11
Head and Neck Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
10
Lung Neoplasms
10
Leukemia, Myeloid, Acute
10
Myasthenia Gravis
9
Melanoma
9
Urinary Bladder Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Liver Neoplasms
6
Cholangiocarcinoma
6
Carcinoma, Transitional Cell
6
Triple Negative Breast Neoplasms
5
Small Cell Lung Carcinoma
5
Lymphoma, Follicular
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
Cytomegalovirus Infections
×
Clear all
NCT05305040
2024-05-16
Prevent
AlloVir
Phase 2/3
Terminated
451 enrolled
10 charts
NCT04693637
2024-05-09
Prevent
AlloVir
Phase 2/3
Completed
26 enrolled
16 charts